Final results of a phase II study of tipifarnib in chronic myelomonocytic leukemia (CMML) and other myelodysplastic/myeloproliferative neoplasms (MDS/MPN)

According to phase 2 data presented during the ESMO Congress 2021, tipifarnib—a selective inhibitor of farnesyl-transferase—demonstrated modest efficacy and is well tolerated among patients with chronic myelomonocytic leukemia and other myelodysplastic/myeloproliferative neoplasms. Overall ORR was 21.9% among 7/32 patients with CMML and 25% among 4/7 patients with MDS/MPN. All patients had at least one treatment-related adverse event (AE), while 34% of patients had at least one treatment-related serious AE.